KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Abbott Laboratories (ABT) Shares Outstanding (Diluted Average) (2016 - 2025)

Abbott Laboratories' Shares Outstanding (Diluted Average) history spans 17 years, with the latest figure at $1.7 billion for Q4 2025.

  • For Q4 2025, Shares Outstanding (Diluted Average) changed 0.0% year-over-year to $1.7 billion; the TTM value through Dec 2025 reached $1.7 billion, changed 0.0%, while the annual FY2025 figure was $1.7 billion, 0.0% changed from the prior year.
  • Shares Outstanding (Diluted Average) for Q4 2025 was $1.7 billion at Abbott Laboratories, roughly flat from $1.7 billion in the prior quarter.
  • Across five years, Shares Outstanding (Diluted Average) topped out at $1.8 billion in Q2 2021 and bottomed at $1.7 billion in Q1 2025.
  • The 5-year median for Shares Outstanding (Diluted Average) is $1.8 billion (2023), against an average of $1.8 billion.
  • The largest annual shift saw Shares Outstanding (Diluted Average) rose 0.61% in 2021 before it fell 1.42% in 2022.
  • A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $1.8 billion in 2021, then dropped by 1.4% to $1.8 billion in 2022, then fell by 0.85% to $1.7 billion in 2023, then decreased by 0.06% to $1.7 billion in 2024, then changed by 0.0% to $1.7 billion in 2025.
  • Per Business Quant, the three most recent readings for ABT's Shares Outstanding (Diluted Average) are $1.7 billion (Q4 2025), $1.7 billion (Q3 2025), and $1.7 billion (Q2 2025).